TuHURA Biosciences, Inc. (HURA) Investor Relations Documents

TuHURA Biosciences, Inc. (HURA) investor relations documents from the company's IR site: 1 presentation, 15 press releases; latest deck 2026-05-15. Read in-app with summaries. First-party data.

Corporate Presentation: TuHURA Bio is a Phase 3 immuno-oncology company developing novel therapies to overcome cancer immunotherapy resistance, with IFx-2.0 top-line data expected 2H 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releaseTuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-07-22Press releaseTuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
2026-06-15Press releaseTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody i
2026-05-15Press releaseTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-29Press releasehttps://www.prnewswire.com/news-releases/tuhura-biosciences-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update-302773858.html
2026-05-15PresentationCorporate Presentation
2026-05-15Press releasePDF
2026-05-12Press releaseTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-29Press releasehttps://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html
2026-05-12Press releaseDownload as PDF
2026-04-22Press releaseTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into
2026-04-07Press releaseTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
2026-04-01Press releaseTuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
2026-03-23Press releaseCraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Progra
2026-02-27Press releaseTuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-04-01Press releaseTuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

HURA overview · HURA earnings · HURA financials · HURA KPIs · HURA ownership · HURA peers · HURA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.